

## Claims

1. An isolated engineered anti-tumor necrosis factor receptor (TNFR) superfamily member antibody, wherein the antibody comprises a T437R mutation, a T437R/K248E mutation or a T437R/K338A mutation in the IgG Fc domain when compared to a parent wild-type antibody, residue numbering according to the EU Index.
2. The antibody of claim 1, comprising the T437R mutation.
3. The antibody of claim 1, comprising the T437R/K248E mutation.
4. The antibody of claim 1, comprising the T437R/K338A mutation.
5. The antibody of claim 1, wherein the antibody is an IgG1, IgG2, IgG3 or IgG4 isotype.
6. The antibody of claim 1, wherein the antibody further comprises a second mutation.
7. The antibody of claim 6, wherein the second mutation is a L234A/L235A mutation on IgG1, a V234A/G237A/P238S/H268A/V309L/A330S/P331S mutation on IgG2, a F234A/L235A mutation on IgG4, a S228P/F234A/L235A mutation on IgG4, a N297A mutation on IgG1, IgG2, IgG3 or IgG4, a V234A/G237A mutation on IgG2, a K214T/E233P/L234V/L235A/G236-deleted/A327G/P331A/D365E/L358M mutation on IgG1, a H268Q/V309L/A330S/P331S mutation on IgG2, a L234F/L235E/D265A mutation on IgG1, a L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation on IgG1, a S228P/F234A/L235A/G237A/P238S mutation on IgG4, or a S228P/F234A/L235A/G236-deleted/G237A/P238S mutation on IgG4.
8. The antibody of claim 7, wherein the second mutation is the V234A/G237A/P238S/H268A/V309L/A330S/P331S mutation on IgG2.
9. The antibody of claim 7, wherein the second mutation is the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation on IgG1.
10. The antibody of claim 7, wherein the second mutation is the S228P/F234A/L235A mutation on IgG4.
11. The antibody of claim 1, wherein the TNFR superfamily member is OX40 (SEQ ID NO: 4), CD27 (SEQ ID NO: 8), CD40 (SEQ ID NO: 5), CD137 (SEQ ID NO: 10), or GITR (SEQ ID NO: 23).
12. The antibody of claim 1, wherein the antibody comprises a heavy chain constant region of SEQ ID NOs: 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73 or 74.
13. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
14. An isolated Fc domain containing molecule comprising a T437R mutation, a T437R/K248E mutation or a T437R/K338A mutation in the IgG Fc domain, residue numbering according to the EU Index.

15. The Fc domain containing molecule of claim 14, comprising the T437R mutation.
16. The Fc domain containing molecule of claim 14, comprising a T437R/K248E mutation.
17. The Fc domain containing molecule of claim 14, comprising a T437R/K338A mutation.
18. The Fc domain containing molecule of claim 14, wherein the Fc domain is an IgG1, IgG2, IgG3 or IgG4 isotype.
19. The Fc domain containing molecule of claim 14, wherein the Fc domain containing molecule is a monoclonal antibody.
20. The Fc domain containing molecule of claim 14, comprising the amino acid sequence of SEQ ID NOs: 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73 or 74.